Novel inhibitors of urokinase-type plasminogen activator and matrix metalloproteinase expression in metastatic cancer cell lines

International Journal of Cancer

Volumn 110, Issue 4, 2004, Pages 610-616

  Cakarovski, Kristina ^a   Leung, Jenny Y ^a   Restall, Christina ^b   Carin Carlson, Anna ^c   Yang, Eunice ^a   Perlmutter, Patrick ^c   Anderson, Robin ^b   Medcalf, Robert ^a   Dear, Anthony E ^a  

^a MONASH UNIVERSITY   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Histone deacetylase inhibitors (HDACi); Matrix metalloproteinase; Metacept 1(MCT 1); Oxamflatin (Ox); Urokinase type plasminogen activatar

Indexed keywords

ANTINEOPLASTIC AGENT; HYDROXAMIC ACID DERIVATIVE; MATRIX METALLOPROTEINASE; MESSENGER RNA; METACEPT 1; OXAMFLATIN; UNCLASSIFIED DRUG; UROKINASE; UROKINASE TYPE PLASMINOGEN ACTIVATOR 2;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL INVASION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INFLAMMATION; METASTASIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UPREGULATION; WOUND HEALING; ZYMOGRAPHY;

CELL LINE, TUMOR; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RNA, MESSENGER; URINARY PLASMINOGEN ACTIVATOR;

EID: 2442662971     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20135     Document Type: Article

References (48)

1. Andreasen PA, Kjøller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1-22.
2. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Mol Cell Biol 2002;3:207-14.
3. Dear AE, Medcalf RL. The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic molecule. Eur J Biochem 1998;252: 185-93.
4. Dear AE, Medcalf RL. The cellular and molecular biology of plasminogen activator inhibitor type-2. Fibrinolysis 1995;9:321-30.
5. Baramova EN, Bajou K, Remacle A, L'Hoir C, Krell HW, Weidle UH, Noel A, Foidart J. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 1997;405:157-62.
6. Menshikov M, Elizarova E, Plakida K, Timofeeva A, Khaspekov G, Beabealashvilli R, Bobik A, Tkachuk V. Urokinase upregulates matrix metalloproteinase-9 expression in THP-1 monocytes via gene transcription and protein synthesis. Biochem J 2002;367: 833-9.
7. Laug WE, Cao XR, Yu YB, Shimada H, Kruithof EKO. Inhibition of invasion of HT-1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res 1993;53:6051-7.
8. Mueller BM, Yu YB, Laug WE. Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/ scid mice. Proc Natl Acad Sci USA 1995;92: 205-9.
9. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol 1996;3:895-904.
10. Duggan C, Kennedy S, Kramer MD, Barnes C, Elvin P, McDermott E, O'Higgins N, Duffy MJ. Plasminogen activator inhibitor type 2 in breast cancer. Br J Cancer 1997;76:622-7.
11. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Jaenicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000;60:636-43.
12. Giavazzi R, Taraboletti G. Pre-clinical development of metalloprotease inhibitors in cancer therapy. Clin Rev Oncol/Hematol 2001;37: 53-60.
13. Holst-Hansen C, Johannessen B, Hoyer-Hansen G, Romer J, Ellis V, Brunner N. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 1996;14:297-307.
14. Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH, Dano K, Grondahl-Hansen J. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994;54: 4671-5.
15. Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP, Sheahan K. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 1994;344: 583-4.
16. Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Spathe K, Dettmar P, Hofler H, Janicke F, Schmitt M, et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 1999;79:1746-51.
17. Stahl A, Muller B. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 1994;54:3066-71.
18. Schmitt M, Wilhelm OG, Reuning U, Krüger A, Harbeck N, Lengyel E, Graeff H, Gänsbacher B, Kessler H, Bürgle M, Stürzebecher J, Sperl S, et al. The urokinase plasminogen activator system as a novel target for tumor therapy. Fibrinol Proteol 2000;14:114-32.
19. Billstrom A, Hartley-Asp B, Lecander I, Batra S, Astedt B. The urokinase inhibitor p-aminobenzamidine inhibits growth of a human prostate tumor in SCID mice. Int J Cancer 1995;61:542-7.
20. Sato S, Kopitz C, Schmalix WA, Muehlenweg B, Kessler H, Schmitt M, Kruger A, Magdolen V. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread. FEBS Lett 2002;528: 212-6.
21. Kellen JA, Mirakian A, Kolin A. Antimetastatic effect of amiloride in an animal tumour model. Anticancer Res 1988;8:1373-6.
22. Rabbani SA, Gladu J. Urokinase receptor antibody can reduce tumour volume and detect the presence of occult tumor metastasis in vivo. Cancer Res 2002;62:2390-7.
23. Xing RH, Mazar A, Henkin J, Rabbani SA. Prevention of breast cancer growth, invasion and metastasis by antiestragen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res 1997;57:3585-93.
24. Guo Y, Mazar AP, Lebrun JJ, Rabbani SA. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumour growth and metastasis in a syngeneic model of breast cancer. Cancer Res 2002;62:4678-84.
25. Campo E, Merino MJ, Tavassoli FA, Charonis AS, Stetler-Stevenson WG, Liotta LA. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol 1992;16:500-7.
26. Talvensaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 1998;83:1153-62.
27. Rabbani SA, Harakidas P, Guo Y, Steinman D, Davidsen SK, Morgan DW. Synthetic inhibitor of matrix metalloproteinases decreases tumour-growth and metastasis in syngeneic model of rat prostate cancer in vivo. Int J Cancer 2000;87:276-82.
28. Sonoda H, Nishida K, Yoshioka T, Ohtani M, Sugita K. Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of Jun D. Oncogene 1996;13:143-9.
29. Dear AE, Medcalf RL. The novel anti-tumour agent oxamflatin differentially regulates urokinase and plasminogen activator inhibitor type 2 expression and inhibits urokinase-mediated proteolytic activity. Biochim Biophys Acta 2000;1492:15-22.
30. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
31. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
32. Schleuning WD, Medcalf RL, Hession C, Rothenbuhler R, Shaw A, Kruithof EKO. Plasminogen activator inhibitor 2: regulation of gene transcription during phorbol ester-mediated differentiation of U-937 histiocytic lymphoma cells. Mol Cell Biol 1987;53:4564-7.
33. Medcalf RL, Richards RR, Crawford RJ, Hamilton JA. Suppression of urokinase-type plasminogen activator mRNA levels in human fibrosarcoma cells and synovial fibroblasts by antinflammatory glucocorticoids. EMBO J 1986;5:2217-22.
34. Medcalf RL, Van Den Berg E, Schleuning WD, Glucocorticoid-modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2. J Cell Biol 1988;106:971-8.
35. Granelli-Piperno E, Reich E. A study of proteases and protease inhibitor complexes in biological fluids. J Exp Med 1978;148:223-34.
36. Fridman R, Toth M, Pena D, Mobashery S. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 1995;55: 2548-55.
37. Sehgal I, Thompson TC. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-β1 in human prostate cancer cell lines. Mol Biol Cell 1999;10: 407-16.
38. Stearns ME, Garcia FU, Fudge K, Rhim J, Wang M. Role of interleukin 10 and transforming growth factor β1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin Cancer Res 1999;5:711-20.
39. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002;2: 657-72.
40. Dear AE, Shen Y, Rüegg M, Medcalf RL. Molecular mechanisms governing tumor-necrosis-factor-mediated regulation of plasminogen activator inhibitor-type-2 gene expression. Eur J Biochem 1996;241: 93-100.
41. Wang Y, Dang J, Xiaoming L, Doe WF. Amiloride modulates urokinase gene expression at both transcription and post-transcription levels in human colon cancer cells. Clin Exp Metastasis 1995;13:96-202.
42. Kim YB, Lee KH, Sugita K, Yoshida M, Horinouchi S. Oxamflatin is a novel anti-tumor compound that inhibits mammalian histone deacetylase. Oncogene 1999;18:2461-70.
43. Ailenberg M, Silverman M. Trichostatin A-histone deacetylase inhibitor with clinical therapeutic potential-is also a selective and potent inhibitor of gelatinase A expression. Biochem Biophys Res Commun 2002;298:110-5.
44. Ailenberg M, Silverman M. Differential effects of trichostatin A on gelatinase A expression in 3T3 fibroblasts and HT-1080 fibrosarcoma cells: implications for use of TSA in cancer therapy. Biochem Biophys Res Commun 2003;302:181-5.
45. Polevoda B, Sherman F. The diversity of acetylated proteins. Genome Biol 2002;3:1-6.
46. Crazzolara R, Johrer K, Johnstone RW, Greil R, Ofler RK, Meister B, Bernhard D. Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia. Br J Haematol 2002;119:965-9.
47. Park JH, Faller DV. Epstein-Barr virus latent membrane protein-1 induction by histone deacetylase inhibitors mediates induction of intercellular adhesion molecule-1 expression and homotypic aggregation. Virology 2002;303:345-63.
48. Bisson C, Blacher S, Polette M, Blanc JF, Kebers F, Desreux J, Tetu B, Rosenbaum J, Foidart JM, Birembaut P, Noel A. Restricted expression of membrane type 1-matrix metalloproteinase by myofibroblasts adjacent to human breast cancer cells. Int J Cancer 2003;105:7-13.